- Home
- PLRX vs RGR Comparison
PLRX vs RGR Comparison
Compare PLRX & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- RGR
- Stock Information
- Founded
- PLRX 2015
- RGR 1949
- Country
- PLRX United States
- RGR United States
- Employees
- PLRX N/A
- RGR N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- PLRX Health Care
- RGR Industrials
- Exchange
- PLRX Nasdaq
- RGR Nasdaq
- Market Cap
- PLRX 641.5M
- RGR 610.8M
- IPO Year
- PLRX 2020
- RGR N/A
- Fundamental
- Price
- PLRX $11.21
- RGR $35.70
- Analyst Decision
- PLRX Strong Buy
- RGR
- Analyst Count
- PLRX 7
- RGR 0
- Target Price
- PLRX $40.50
- RGR N/A
- AVG Volume (30 Days)
- PLRX 560.2K
- RGR 175.0K
- Earning Date
- PLRX 02-26-2025
- RGR 02-19-2025
- Dividend Yield
- PLRX N/A
- RGR 1.94%
- EPS Growth
- PLRX N/A
- RGR N/A
- EPS
- PLRX N/A
- RGR 1.73
- Revenue
- PLRX N/A
- RGR $520,485,000.00
- Revenue This Year
- PLRX N/A
- RGR N/A
- Revenue Next Year
- PLRX N/A
- RGR $4.81
- P/E Ratio
- PLRX N/A
- RGR $20.61
- Revenue Growth
- PLRX N/A
- RGR N/A
- 52 Week Low
- PLRX $10.22
- RGR $34.11
- 52 Week High
- PLRX $18.92
- RGR $48.20
- Technical
- Relative Strength Index (RSI)
- PLRX 37.19
- RGR 48.45
- Support Level
- PLRX $11.02
- RGR $35.24
- Resistance Level
- PLRX $12.70
- RGR $36.18
- Average True Range (ATR)
- PLRX 0.80
- RGR 0.77
- MACD
- PLRX -0.18
- RGR 0.25
- Stochastic Oscillator
- PLRX 8.21
- RGR 70.04
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The Company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.